Datapoint: Novartis Reportedly Mulls Sandoz Spinoff
Novartis is reportedly considering spinning off its $25 billion generics unit, Sandoz, according to a June 30 report in Bloomberg. Novartis has been conducting a strategic review of Sandoz since last fall, and plans to share results by the end of this year. Novartis saw $9.2 billion in generic drug sales in 2021, and sales of $9.4 billion are projected for 2022. Its top-selling retail generics in the U.S. are omeprazole, tamsulosin hydrochloride and latanoprost.
© 2025 MMIT